Earnings per share for the last twelve months: Burning Rock Biotech Limited (BNR)

Burning Rock Biotech revenues are being constrained by the macroeconomic downturn in China and regulatory barriers in the US. The TTM earnings per share trend on GURU.Markets reflects the current trajectory, where the value of -0.90 characterizes this level. Stable cash flow is driven by the implementation of sequencing tests in oncology centers, while regional leadership is secured by patents and exclusive access to biodata.

Burning Rock Biotech (BNR) is developing a high-tech NGS diagnostics network by integrating platforms into the IT infrastructure of Chinese clinics. This chart reflects the net income per share over the last 12 months, calculated by dividing total profit by the total number of securities. This indicator measures the actual efficiency of capital generation for each shareholder. The growth of this metric confirms the business model's resilience to borrowing costs. The price action of net income per share over the last 12 months allows for the timely identification of margin compression risks.